Stock Performance: TRANSTHERA-B (02617.HK) opened lower but surged to HKD201.2, marking a 16.5% increase with a turnover of HKD529 million.
Share Conversion Approval: The company announced the approval to convert 44.97 million domestic shares into H-shares, which will be eligible for trading on the Hong Kong Stock Exchange upon regulatory approval.
Financial Overview: Since its listing in June, TRANSTHERA-B has not generated revenue and reported a loss of RMB123 million for the half-year ending June, an improvement from a loss of RMB160 million the previous year.
Market Activity: The stock experienced significant volatility, peaking at HKD679.5 in mid-September and briefly achieving a market cap over HKD200 billion, surpassing established pharmaceutical companies.
Wall Street analysts forecast 01093 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01093 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 01093 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01093 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 9.810
Low
Averages
High
Current: 9.810
Low
Averages
High
Daiwa
Daiwa
Buy
to
Hold
downgrade
$100 -> $116
Al Analysis
2026-01-05
Reason
Daiwa
Daiwa
Price Target
$100 -> $116
Al Analysis
2026-01-05
downgrade
Buy
to
Hold
Reason
The analyst rating from Daiwa reflects a more cautious approach for 2026, recommending a selective strategy focused on quality stocks after a strong performance in the Chinese biopharmaceutical sector in 2025. The downgrade of AKESO from Buy to Hold is attributed to a lack of short-term catalysts, despite an increase in its target price. Conversely, Daiwa has raised the target price for INNOVENT BIO, indicating confidence in its potential, while maintaining a Sell rating for CSPC PHARMA, suggesting a negative outlook for that stock.
BofA Securities
BofA Securities
Buy
maintain
$45
2025-12-24
Reason
BofA Securities
BofA Securities
Price Target
$45
2025-12-24
maintain
Buy
Reason
The analyst rating for HANSOH PHARMA was maintained at "Buy" due to the company achieving the highest year-over-year sales growth among its peers at 8.6% in October, with most of its key products recording double-digit month-over-month growth. In contrast, HENGRUI PHARMA received an "Underperform" rating because several of its key products faced pressure, despite a 2% year-over-year increase in total sample sales. SINO BIOPHARM was also rated "Buy" due to the significant licensing potential of its pipeline products, despite a reduction in sales forecasts for some products. CSPC PHARMA was rated "Underperform" due to sluggish sales performance in October.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01093
Unlock Now
Morgan Stanley
Morgan Stanley
Overweight
downgrade
$11
2025-12-17
Reason
Morgan Stanley
Morgan Stanley
Price Target
$11
2025-12-17
downgrade
Overweight
Reason
The analyst rating for CSPC PHARMA was updated to "Overweight" by Morgan Stanley due to a revision in the company's sales forecasts for 2025-26, which were cut by 1% and 2%, respectively. Despite these reductions, the 2027 sales forecast remained unchanged. Additionally, estimates for recurring net profit were lowered by 4% for 2025-26, while the 2027 estimate stayed the same. The target price was also decreased from HKD11 to HKD10.4, reflecting the adjustments made based on the company's 3Q25 results and management guidance.
Daiwa
downgrade
$17.4
2025-10-27
Reason
Daiwa
Price Target
$17.4
2025-10-27
downgrade
Reason
The analyst rating from CLSA reflects a cautious yet optimistic outlook on China's biotechnology and innovative drug industry. The reasons for the ratings include:
1. Market Volatility and Overvaluation: The industry has faced volatility due to overvaluation from previous price hikes and uncertainty regarding national medical insurance drug pricing.
2. Attractive Valuations: Despite the volatility, CLSA notes that valuations of quality companies are becoming attractive, suggesting potential for investment.
3. Ongoing Business Expansion: There are ongoing business expansion activities, which could lead to future growth opportunities.
4. Limited Downside Risk: CLSA believes that further downside price risk seems limited, indicating a more stable outlook moving forward.
5. Healthy Consolidation: The current pullback in stock prices is viewed as a healthy consolidation phase, providing attractive opportunities for investment in the coming year.
6. Specific Company Insights: For CSPC PHARMA, despite delays in business expansion affecting investor confidence, CLSA sees this as creating more attractive buying opportunities. For SINOPHARM, improvements in accounts receivable and the initiation of China's 15th Five-Year Plan are expected to support recovery in earnings momentum.
Overall, the ratings reflect a belief in the potential for recovery and growth in the sector, despite current challenges.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
